Table 2.

Categories for assessment of possible predictive risk factors.

Gender

Primary and secondary sites of infection at the time of diagnosis and whether the infection remains localised or disseminated

Disseminated infection

Cutaneous infection

Infection confined to the cutaneous or subcutaneous tissue (localised disease)

Invasion into muscle, tendon or bone (deep extension)

Patients with cutaneous disease involving another non-contiguous site (disseminated infection)

Pulmonary infection

Disease confined to the lungs (localised infection) and single vs. multiple lesions

Pulmonary disease that extended to the chest wall, pulmonary artery, aorta or heart

Sino-orbital involvement

Sino-pulmonary disease

Primary underlying condition

Types of immunosuppression or immune impairment

Diabetes mellitus (type and presence of ketoacidosis)

Neutropenic status

Genus, species of organism

Type of antifungal therapy

Timing of initiation of antifungal therapy

Previous antifungal therapy

Surgery

Hyperbaric oxygen therapy

Immunomodulatory agents